Andreas Argyrides
Stock Analyst at Chardan Capital
(4.20)
# 1,535
Out of 5,090 analysts
381
Total ratings
42.4%
Success rate
7.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYPT EyePoint | Reiterated: Hold | n/a | $0.3484 | - | 3 | Oct 19, 2026 | |
| MNKD MannKind | Initiated Coverage: Buy | $10 | $3.50 | +185.71% | 9 | Oct 19, 2026 | |
| GOSS Gossamer Bio | Initiated Coverage: Buy | $160 | $10.38 | +1,441.43% | 20 | Oct 13, 2026 | |
| IKT Inhibikase Therapeutics | Initiated Coverage: Hold | $1.5 | $1.55 | -3.23% | 1 | Oct 13, 2026 | |
| AGEN Agenus | Initiated Coverage: Buy | $40 | $6.84 | +484.80% | 1 | Sep 18, 2026 | |
| IRD Opus Genetics | Rated: Buy | $13 → $16 | $3.67 | +335.97% | 3 | Sep 9, 2026 | |
| RANI Rani Therapeutics Holdings | Initiated Coverage: Buy | $6 | $0.59 | +916.95% | 14 | Aug 18, 2026 | |
| AQST Aquestive Therapeutics | Reiterated: Buy | $8 | $3.89 | +105.66% | 20 | Jun 25, 2026 | |
| SVRA Savara | Reiterated: Buy | $11 | $4.82 | +128.22% | 6 | Jun 3, 2026 | |
| BNTC Benitec Biopharma | Rated: Hold | n/a | $8.74 | - | 3 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.04 | - | 17 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $45.06 | - | 17 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.47 | - | 8 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.78 | - | 28 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $70.32 | - | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.38 | - | 18 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $598.72 | - | 19 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $98 | $74.85 | +30.93% | 5 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $16.69 | +139.66% | 7 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $38.76 | +59.96% | 2 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $6.73 | +524.07% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 → $7 | $1.66 | +321.69% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.39 | +547.48% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $18.62 | n/a | 18 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $750 | $0.1655 | n/a | 14 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.018 | n/a | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $155 | $14.32 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $105 | $14.06 | n/a | 13 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.116 | n/a | 13 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $8.26 | n/a | 7 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 | $7.20 | n/a | 25 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $36.39 | n/a | 8 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $78 → $80 | $58.51 | n/a | 22 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $4 | $7.51 | n/a | 11 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $207 → $225 | $251.27 | n/a | 30 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.46 | n/a | 6 | Aug 25, 2022 |
EyePoint
Oct 19, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.3484
Upside: -
MannKind
Oct 19, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $3.50
Upside: +185.71%
Gossamer Bio
Oct 13, 2026
Initiated Coverage: Buy
Price Target: $160
Current: $10.38
Upside: +1,441.43%
Inhibikase Therapeutics
Oct 13, 2026
Initiated Coverage: Hold
Price Target: $1.5
Current: $1.55
Upside: -3.23%
Agenus
Sep 18, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $6.84
Upside: +484.80%
Opus Genetics
Sep 9, 2026
Rated: Buy
Price Target: $13 → $16
Current: $3.67
Upside: +335.97%
Rani Therapeutics Holdings
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $0.59
Upside: +916.95%
Aquestive Therapeutics
Jun 25, 2026
Reiterated: Buy
Price Target: $8
Current: $3.89
Upside: +105.66%
Savara
Jun 3, 2026
Reiterated: Buy
Price Target: $11
Current: $4.82
Upside: +128.22%
Benitec Biopharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $8.74
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $11.04
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $45.06
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $2.47
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $11.78
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $70.32
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $3.38
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $598.72
Upside: -
Apr 24, 2026
Reiterated: Buy
Price Target: $105 → $98
Current: $74.85
Upside: +30.93%
Mar 3, 2026
Reiterated: Buy
Price Target: $40
Current: $16.69
Upside: +139.66%
Feb 25, 2026
Reiterated: Buy
Price Target: $62
Current: $38.76
Upside: +59.96%
Jan 23, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $6.73
Upside: +524.07%
Nov 11, 2025
Reiterated: Buy
Price Target: $3 → $7
Current: $1.66
Upside: +321.69%
Nov 11, 2025
Reiterated: Buy
Price Target: $9
Current: $1.39
Upside: +547.48%
Oct 9, 2025
Reiterated: Buy
Price Target: $37
Current: $18.62
Upside: n/a
Aug 11, 2025
Reiterated: Buy
Price Target: $750
Current: $0.1655
Upside: n/a
Mar 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.018
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: $155
Current: $14.32
Upside: n/a
Aug 13, 2024
Reiterated: Hold
Price Target: $105
Current: $14.06
Upside: n/a
Mar 14, 2024
Reiterated: Buy
Price Target: $2
Current: $0.116
Upside: n/a
Mar 6, 2024
Rated: Buy
Price Target: $29
Current: $8.26
Upside: n/a
Mar 5, 2024
Reiterated: Hold
Price Target: $21
Current: $7.20
Upside: n/a
Mar 1, 2024
Reiterated: Buy
Price Target: $57
Current: $36.39
Upside: n/a
Feb 23, 2024
Reiterated: Hold
Price Target: $78 → $80
Current: $58.51
Upside: n/a
Feb 22, 2024
Reiterated: Buy
Price Target: $7 → $4
Current: $7.51
Upside: n/a
Feb 8, 2024
Rated: Buy
Price Target: $207 → $225
Current: $251.27
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $1.46
Upside: n/a